[go: up one dir, main page]

MX2022009399A - TOPICAL FORMULATION OF ROFLUMILAST WHICH HAS GREATER RELEASE AND PLASMA HALF-LIFE. - Google Patents

TOPICAL FORMULATION OF ROFLUMILAST WHICH HAS GREATER RELEASE AND PLASMA HALF-LIFE.

Info

Publication number
MX2022009399A
MX2022009399A MX2022009399A MX2022009399A MX2022009399A MX 2022009399 A MX2022009399 A MX 2022009399A MX 2022009399 A MX2022009399 A MX 2022009399A MX 2022009399 A MX2022009399 A MX 2022009399A MX 2022009399 A MX2022009399 A MX 2022009399A
Authority
MX
Mexico
Prior art keywords
roflumilast
life
plasma half
topical formulation
greater release
Prior art date
Application number
MX2022009399A
Other languages
Spanish (es)
Inventor
David W Osborne
Bhaskar Chaudhuri
Archie W Thurston
Original Assignee
Arcutis Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/778,845 external-priority patent/US11129818B2/en
Application filed by Arcutis Biotherapeutics Inc filed Critical Arcutis Biotherapeutics Inc
Publication of MX2022009399A publication Critical patent/MX2022009399A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención está dirigida a métodos para mejorar el resultado terapéutico del tratamiento con roflumilast. El resultado terapéutico mejora con la liberación constante y/o semivida plasmática más larga de una composición de roflumilast administrada tópicamente. La composición de roflumilast incluye preferiblemente fosfato dicetílico, fosfato de ceteth-10, éter monoetílico de díetilenglicol y/o hexilenglicol.The present invention is directed to methods for improving the therapeutic outcome of roflumilast treatment. The therapeutic outcome improves with constant release and/or longer plasma half-life of a topically administered roflumilast composition. The roflumilast composition preferably includes dicetyl phosphate, ceteth-10 phosphate, diethylene glycol monoethyl ether and/or hexylene glycol.

MX2022009399A 2020-01-31 2021-01-29 TOPICAL FORMULATION OF ROFLUMILAST WHICH HAS GREATER RELEASE AND PLASMA HALF-LIFE. MX2022009399A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/778,845 US11129818B2 (en) 2017-06-07 2020-01-31 Topical roflumilast formulation having improved delivery and plasma half life
PCT/US2021/015740 WO2021155173A1 (en) 2020-01-31 2021-01-29 Topical roflumilast formulation having improved delivery and plasma half-life

Publications (1)

Publication Number Publication Date
MX2022009399A true MX2022009399A (en) 2022-09-19

Family

ID=74759470

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009399A MX2022009399A (en) 2020-01-31 2021-01-29 TOPICAL FORMULATION OF ROFLUMILAST WHICH HAS GREATER RELEASE AND PLASMA HALF-LIFE.

Country Status (10)

Country Link
EP (1) EP4096630A1 (en)
JP (1) JP2023513092A (en)
KR (1) KR20220134617A (en)
CN (1) CN115551478A (en)
AU (1) AU2021214399B2 (en)
BR (1) BR112022015104A2 (en)
CA (1) CA3166300A1 (en)
IL (1) IL295172A (en)
MX (1) MX2022009399A (en)
WO (1) WO2021155173A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250057103A (en) * 2022-09-15 2025-04-28 아큐티스 바이오테라퓨틱스, 인크. Pharmaceutical composition comprising roflumilast and a solvent capable of dissolving a large amount of the drug
WO2025054483A1 (en) * 2023-09-07 2025-03-13 Arcutis Biotherapeutics, Inc. Dosing regimens using topical roflumilast compositions
US20250090509A1 (en) * 2023-09-15 2025-03-20 Arcutis Biotherapeutics, Inc. Methods of reducing itch using topical roflumilast compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0706513T1 (en) 1993-07-02 2002-10-31 Altana Pharma Ag Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
DK2020243T3 (en) 2002-05-28 2018-11-19 Astrazeneca Ab Pharmaceutical composition which can be applied topically
DE102004046235A1 (en) 2004-09-22 2006-03-30 Altana Pharma Ag drug preparation
EA016037B1 (en) * 2005-04-19 2012-01-30 Никомед Гмбх Roflumilast for the treatment of pulmonary hypertension
US20200155524A1 (en) * 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US9895359B1 (en) * 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US11534493B2 (en) * 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
AU2019281888B2 (en) * 2018-06-04 2024-05-02 Arcutis Biotherapeutics, Inc. Method and formulation for improving roflumilast skin penetration lag time

Also Published As

Publication number Publication date
AU2021214399A1 (en) 2022-08-25
KR20220134617A (en) 2022-10-05
WO2021155173A1 (en) 2021-08-05
BR112022015104A2 (en) 2022-09-27
AU2021214399B2 (en) 2025-09-11
CA3166300A1 (en) 2021-08-05
EP4096630A1 (en) 2022-12-07
CN115551478A (en) 2022-12-30
JP2023513092A (en) 2023-03-30
IL295172A (en) 2022-09-01

Similar Documents

Publication Publication Date Title
CL2023000848A1 (en) Combination therapy including krasg12c inhibitor and pharmaceutically active agent to treat cancer
MX2022009399A (en) TOPICAL FORMULATION OF ROFLUMILAST WHICH HAS GREATER RELEASE AND PLASMA HALF-LIFE.
CY1125358T1 (en) COMBINATION THERAPY INCLUDING AN MDM2 INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCER
CL2023002383A1 (en) Quinazoline compound to induce degradation of g12d mutant kras protein
BR112018001640A2 (en) combination of pd-1 antagonist with an egfr inhibitor
MX2024004846A (en) TETRACYCLIC COMPOUND CONTAINING NITROGEN, METHOD OF PREPARATION THEREOF AND ITS MEDICAL USE.
MX2018003331A (en) Administration of deuterated cftr potentiators.
MX2020013120A (en) Therapeutic treatment of microsatellite unstable cancers.
MX2019003397A (en) Methods of treating mitochondrial and metabolic disorders.
CL2017000317A1 (en) Adjunctive therapy with 25-hydroxy vitamin d
PE20181351A1 (en) ADJUNCTIVE THERAPY WITH 25-HYDROXY VITAMIN D AND ARTICLES OF THE SAME
MX2020010729A (en) Stable anti-cd79b immunoconjugate formulations.
MX2021005240A (en) Combination of small molecule cd-47 inhibitors with other anti-cancer agents.
MX2022008478A (en) Low-dose brimonidine combinations and uses thereof.
MX387113B (en) AQUEOUS CAPSAICINOID COMPOSITIONS COMPRISING AN ANALGESIC AND AN AQUEOUS VEHICLE, AND USE THEREOF FOR THE TREATMENT OF PAIN.
MX2021015770A (en) MACROCYCLIC MCL-1 INHIBITORS.
MX2021011230A (en) SUBCUTANEOUS ADMINISTRATION OF NANOPARTICLES THAT COMPRISE AN INHIBITOR OF THE TARGET OF RAPAMYCIN IN MAMMALS (MTOR) AND ALBUMIN FOR THE TREATMENT OF DISEASES.
ECSP22044525A (en) COMBINATION THERAPY COMPRISING AN ALK2 INHIBITOR AND A JAK2 INHIBITOR
CL2022003511A1 (en) Alk2 inhibitors for the treatment of anemia.
EP4356966A3 (en) Dosing regimens associated with extended release paliperidone injectable formulations
MX2022011845A (en) COMBINATION THERAPY WITH A MUTANT IDH INHIBITOR AND A BCL-2 INHIBITOR.
MX2018015916A (en) Porphyrin compounds and compositions useful for treating cancer.
CO2022007501A2 (en) Methods and compositions for the treatment of rett syndrome
CO2024013267A2 (en) Abiraterone decanoate prodrugs and use in therapy
CL2023002914A1 (en) Dosing and administration of recombinant l-asparaginase